Numerous studies have linked the upregulation of YAP/TAZ to tumorigenesis, disease progression, and unfavorable clinical outcomes in NSCLC (Su et al., 2012; Wang et al., 2010; Lorenzetto et al., 2014; Guo et al., 2017; Cui et al., 2012). The gene discussed is YAP1; the disease is non-small cell lung carcinoma.